Investigating the basis of MAIT cell antigen potency

研究 MAIT 细胞抗原效力的基础

基本信息

  • 批准号:
    10617747
  • 负责人:
  • 金额:
    $ 53.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-15 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

SUMMARY Mucosal Associated Invariant T (MAIT) cells comprise up to 10% of human peripheral blood T cells, and are enriched in the liver, lungs and gastrointestinal mucosa. This indicates that MAIT cells are key players in immunity. However, their roles in immune protection, and in immunopathology are yet to be fully established. Nevertheless, MAIT cells are implicated in chronic inflammatory diseases including tuberculosis, peptic ulceration, periodontal disease and inflammatory bowel disease. Central to the function of MAIT cells is the MAIT T cell antigen receptor (TCR). Consistent with their innate-like phenotype, MAIT cells express a very restricted T cell repertoire. Namely, human MAIT cells are characterized by an invariant TCR a-chain (TRAV1-2-TRAJ33) paired with a limited array of TCR b-chains (TRBV6 or TRBV20). The MAIT TCR is restricted to the monomorphic Major Histocompatibility Complex class I related protein, MR1. A very high level of conservation of MR1 in mammals and the restricted MAIT TCR usage strongly indicate an important and evolutionarily conserved function for the MAIT TCR-MR1 axis in immunity. Based on our previous work and preliminary findings, we aim to: (i) Investigate novel MAIT cell antigens and their impact on MAIT TCR diversity; (ii) Define the cellular machinery involved in acquisition and presentation of MR1 antigens; (iii) Investigate the structural basis of MAIT cell antigen potency and selectivity. Our proposed studies will advance our understanding of MR1 presentation and subsequent recognition by the MAIT TCR, which is a fundamental precursor for harnessing MAIT cells for future immunotherapeutics.
总结 粘液相关不变T(MAIT)细胞包含高达10%的人外周血T细胞,并且是 在肝、肺和胃肠道粘膜中富集。这表明MAIT细胞是参与 免疫力然而,它们在免疫保护和免疫病理学中的作用尚未完全确定。 然而,MAIT细胞与慢性炎性疾病包括结核病、消化性溃疡、结肠炎和结肠炎有关。 溃疡、牙周病和炎性肠病。MAIT细胞功能的核心是MAIT T细胞抗原受体(TCR)。与它们的先天样表型一致,MAIT细胞表达非常有限的 T细胞库。即,人MAIT细胞的特征在于不变的TCR α链(TRAV 1 -2-TRAJ 33)。 与有限的TCR b链阵列(TRBV 6或TRBV 20)配对。MAIT TCR仅限于单晶型 主要组织相容性复合物I类相关蛋白,MR 1。MR 1基因的高度保守性, 哺乳动物和有限的MAIT TCR使用强烈表明一个重要的和进化上保守的 MAIT TCR-MR 1轴在免疫中的作用。基于我们以前的工作和初步的发现,我们的目标是 目的:(i)研究新的MAIT细胞抗原及其对MAIT TCR多样性的影响;(ii)确定细胞免疫应答的分子机制; 参与MR 1抗原获得和呈递的机制;(iii)研究MAIT的结构基础 细胞抗原效力和选择性。我们提出的研究将促进我们对MR 1表达的理解 以及随后被MAIT TCR识别,这是利用MAIT细胞进行 未来的免疫疗法

项目成果

期刊论文数量(35)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MAIT cells regulate NK cell-mediated tumor immunity.
  • DOI:
    10.1038/s41467-021-25009-4
  • 发表时间:
    2021-08-06
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Petley EV;Koay HF;Henderson MA;Sek K;Todd KL;Keam SP;Lai J;House IG;Li J;Zethoven M;Chen AXY;Oliver AJ;Michie J;Freeman AJ;Giuffrida L;Chan JD;Pizzolla A;Mak JYW;McCulloch TR;Souza-Fonseca-Guimaraes F;Kearney CJ;Millen R;Ramsay RG;Huntington ND;McCluskey J;Oliaro J;Fairlie DP;Neeson PJ;Godfrey DI;Beavis PA;Darcy PK
  • 通讯作者:
    Darcy PK
When it's good to have MAITs.
  • DOI:
    10.1111/imcb.12402
  • 发表时间:
    2020-11
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Souter MN;McCluskey J;Corbett AJ
  • 通讯作者:
    Corbett AJ
Dynamic MAIT Cell Recovery after Severe COVID-19 Is Transient with Signs of Heterogeneous Functional Anomalies.
  • DOI:
    10.4049/jimmunol.2300639
  • 发表时间:
    2024-02-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kammann T;Gorin JB;Parrot T;Gao Y;Ponzetta A;Emgård J;Maleki KT;Sekine T;Rivera-Ballesteros O;Karolinska COVID-19 Study Group;Gredmark-Russ S;Rooyackers O;Skagerberg M;Eriksson LI;Norrby-Teglund A;Mak JYW;Fairlie DP;Björkström NK;Klingström J;Ljunggren HG;Aleman S;Buggert M;Strålin K;Sandberg JK
  • 通讯作者:
    Sandberg JK
Differential antigenic requirements by diverse MR1-restricted T cells.
  • DOI:
    10.1111/imcb.12519
  • 发表时间:
    2022-03
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Seneviratna, Rebecca;Redmond, Samuel J.;McWilliam, Hamish E. G.;Reantragoon, Rangsima;Villadangos, Jose A.;McCluskey, James;Godfrey, Dale, I;Gherardin, Nicholas A.
  • 通讯作者:
    Gherardin, Nicholas A.
Determination of Sample Concentrations by PULCON NMR Spectroscopy.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James McCluskey其他文献

James McCluskey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James McCluskey', 18)}}的其他基金

Investigating the basis of MAIT cell antigen potency
研究 MAIT 细胞抗原效力的基础
  • 批准号:
    10405515
  • 财政年份:
    2020
  • 资助金额:
    $ 53.92万
  • 项目类别:
Investigating the basis of MAIT cell antigen potency
研究 MAIT 细胞抗原效力的基础
  • 批准号:
    10192646
  • 财政年份:
    2020
  • 资助金额:
    $ 53.92万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 53.92万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 53.92万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 53.92万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 53.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 53.92万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 53.92万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 53.92万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 53.92万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 53.92万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 53.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了